Trials / Terminated
TerminatedNCT01665274
Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer
A Randomized Single Center Controlled Study of Perioperative Chemotherapy of Oxaliplatin Combined With Capecitabine (XELOX) Versus XELOX as Post-operative Chemotherapy in Advanced Gastric Adenocarcinoma With D2 Dissection
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Harbin Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate that capecitabine/oxaliplatin as perioperative chemotherapy is superior or not to operation directly for locally advanced gastric cancer in terms of 3 year disease-free survival (DFS) rate.
Detailed description
The patients of gastric cancer have been divided into two parts in random.The test group receive perioperative chemotherapy (XELOX) six cycles and the control group administrate the same program after operation. The two groups have the same staging and eligibility criteria.The 3 year disease-free survival (DFS) rate and 5 year overall survival (OS) rate maybe the last evaluation standard.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capecitabine | Capecitabine 1,000 mg/m² twice daily, d1-14, q3w |
| DRUG | Oxaliplatin | Oxaliplatin IV infusion, 130mg/m² d1, q3w |
| PROCEDURE | D2 resection | D2 resection |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2020-08-01
- Completion
- 2022-09-01
- First posted
- 2012-08-15
- Last updated
- 2022-10-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01665274. Inclusion in this directory is not an endorsement.